Skip to main content

Ozempic, Wegovy Won't Boost Thyroid Cancer Risk: Study

Medically reviewed by Carmen Pope, BPharm. Last updated on April 10, 2024.

By Ernie Mundell HealthDay Reporter

WEDNESDAY, April 10, 2024 -- Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight.

There were concerns that longer term use of the drugs might raise users' odds for thyroid cancer, but a Swedish study of more than 435,000 people finds no evidence to support that notion.

“Many people take these medicines, so it is important to study potential risks associated with them,” said study lead author Björn Pasternak. He's principal researcher at the department of medicine at the Karolinska Institute in Stockholm.

“Our study covers a broad group of patients and provides strong support that GLP-1 analogues are not associated with an increased risk of thyroid cancer," he said in an institute news release.

The findings were published April 9 in the BMJ.

In the analysis, Pasternak's team used data from a major Scandinavian database involving 145,000 people who were taking GLP-1 analogues such as liraglutide (Victoza) or semaglutide (Ozempic), and 290,000 people who were taking one of another class of diabetes drugs called DPP4 inhibitors.

The study found no higher odds for thyroid cancer among folks taking GLP-1 analogues compared to those on DPP4 inhibitors.

That finding was repeated when GLP-1 analogue users were compared to patients taking a third class of diabetes meds, called SGLT2 inhibitors.

Study co-author Peter Ueda, an assistant professor of medicine at the Karolinska Institute, stressed that the final verdict on GLP-1 analogues' effect on the thyroid is still to come.

“We cannot rule out that the risk of certain subtypes of thyroid cancer is increased in smaller patient groups that we could not study here, for example in people with a high congenital risk of medullary thyroid cancer who are advised against using these drugs,” Ueda said.

Sources

  • Karolinska Institute, news release, April 9, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

One Key to Weight Loss for Men: Competing for Cash

WEDNESDAY, May 15, 2024 -- A competitive game with a potential cash reward appeared to help overweight British men lose weight, researchers report. The incentive was winning the...

More Studies Support Wegovy's Long-Term Weight-Loss Benefits

TUESDAY, May 14, 2024 -- Semaglutide -- the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy -- can produce long-term weight and heart health benefits, a...

Smoking During Pregnancy Could Raise Baby's Odds for Obesity Later

TUESDAY, May 14, 2024 -- Women who smoke during pregnancy run a higher risk of their kids becoming overweight or obese, and researchers now think they know one reason...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.